RSNN Annual Workshop 2025: presentations and photos are now available

The Annual Workshop focused on the current developments around Single Arm Trials (SATs). A SAT is a type of clinical study where all participants receive the same treatment or intervention. Unlike randomized controlled trials (RCTs), which include both a treatment group and a control group, SATs do not have a comparison group. During the Annual Workshop, we explored the promises, challenges, and impact across the value chain. 

Experts with various backgrounds joined us during the Workshop, which sparked interesting discussions. SATs make it possible to bring new innovations to patients in case of for instance rare diseases for which RCTs are not possible to perform. However, some uncertainties are associated with SATs that complicate to determine effectiveness and cost-effectiveness of a new innovation. 

A meeting report will be published and shared December 2025.

Presentation slides

• Harm van Tinteren (Princess Máxima Centrum) - Single-arm clinical trials: data, statistics and ethics
• Emmely de Vries (CBG-MEB, EMA) - Regulatory perspective on Single Arm Trials  and the implications for the benefits and risks
• Scott Jung (Gilead, Kite Pharma) - Current and Potential Future Considerations of Single Arm Clinical Trial
• Miriam  Koopman (UMC Utrecht) - One arm, many views: the future of evidence generation
• Frank Hulstaert (KCE) - Single arm trials: A Health Technology Assessment perspective
• Lydia Stiny (Zorginstituut Nederland) - Can we use every single-arm trial (SAT) in HTA’s?
• Daan Breederveld (Independent patient) - Patients’ considerations to participate in SATs & treatments based on SAT evidence

Photos